JP6381445B2 - ニューロペプチドsレセプター(npsr)アンタゴニストの組成物および方法 - Google Patents

ニューロペプチドsレセプター(npsr)アンタゴニストの組成物および方法 Download PDF

Info

Publication number
JP6381445B2
JP6381445B2 JP2014546080A JP2014546080A JP6381445B2 JP 6381445 B2 JP6381445 B2 JP 6381445B2 JP 2014546080 A JP2014546080 A JP 2014546080A JP 2014546080 A JP2014546080 A JP 2014546080A JP 6381445 B2 JP6381445 B2 JP 6381445B2
Authority
JP
Japan
Prior art keywords
phenyl
tetrahydrofuro
isobutyl
pharmaceutical composition
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014546080A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500293A5 (cg-RX-API-DMAC7.html
JP2015500293A (ja
Inventor
ラニヨン,スコット
ツァン,イェナン
ハスラー,カーラ
ギルモア,ブライアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RTI International
Original Assignee
RTI International
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RTI International filed Critical RTI International
Publication of JP2015500293A publication Critical patent/JP2015500293A/ja
Publication of JP2015500293A5 publication Critical patent/JP2015500293A5/ja
Application granted granted Critical
Publication of JP6381445B2 publication Critical patent/JP6381445B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2014546080A 2011-12-08 2012-12-06 ニューロペプチドsレセプター(npsr)アンタゴニストの組成物および方法 Active JP6381445B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161568540P 2011-12-08 2011-12-08
US61/568,540 2011-12-08
PCT/US2012/068257 WO2013086200A1 (en) 2011-12-08 2012-12-06 Composition and method for neuropeptide s receptor (npsr) antagonists

Publications (3)

Publication Number Publication Date
JP2015500293A JP2015500293A (ja) 2015-01-05
JP2015500293A5 JP2015500293A5 (cg-RX-API-DMAC7.html) 2015-12-24
JP6381445B2 true JP6381445B2 (ja) 2018-08-29

Family

ID=48574884

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014546080A Active JP6381445B2 (ja) 2011-12-08 2012-12-06 ニューロペプチドsレセプター(npsr)アンタゴニストの組成物および方法

Country Status (7)

Country Link
US (1) US9150582B2 (cg-RX-API-DMAC7.html)
EP (1) EP2788359B1 (cg-RX-API-DMAC7.html)
JP (1) JP6381445B2 (cg-RX-API-DMAC7.html)
AU (1) AU2012347758B2 (cg-RX-API-DMAC7.html)
CA (1) CA2858571C (cg-RX-API-DMAC7.html)
ES (1) ES2624853T3 (cg-RX-API-DMAC7.html)
WO (1) WO2013086200A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017246706B2 (en) * 2016-04-04 2020-09-17 Research Triangle Institute Neuropeptide s receptor (NPSR) agonists
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4917489B1 (cg-RX-API-DMAC7.html) * 1970-01-22 1974-05-01
EP0140833B1 (de) * 1983-09-15 1988-03-02 Ciba-Geigy Ag 5-und 6-Azaphthalide, ihre Isomerengemische, Verfahren zu ihrer Herstellung und ihre Verwendung in druck- und wärmeempfindlichen Aufzeichnungsmaterialien
EP0558521A1 (en) * 1990-11-22 1993-09-08 Janssen Pharmaceutica N.V. Isonicotinic acid derivatives and related spiro compounds with herbicidal action
EP1329508B1 (en) 2000-10-13 2010-09-08 Takeda Pharmaceutical Company Limited Novel g protein-coupled receptor protein and dna thereof
US6642255B2 (en) * 2001-01-11 2003-11-04 Bristol-Myers Squibb Pharma Company 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha
US9012407B2 (en) * 2004-04-23 2015-04-21 The Regents Of The University Of California Therapies which act on neuropeptide S receptors
EP2365748A4 (en) * 2008-11-13 2012-05-02 Merck Sharp & Dohme IMIDAZOISOINDOL neuropeptide S RECEPTOR ANTAGONISTS
EP2365749A4 (en) * 2008-11-13 2012-05-30 Merck Sharp & Dohme Quinolone NEURO PEPTIDE-S-Receptor Antagonists

Also Published As

Publication number Publication date
EP2788359A4 (en) 2015-06-10
CA2858571C (en) 2021-03-16
AU2012347758A1 (en) 2014-06-05
US9150582B2 (en) 2015-10-06
AU2012347758B2 (en) 2017-01-19
JP2015500293A (ja) 2015-01-05
CA2858571A1 (en) 2013-06-13
WO2013086200A1 (en) 2013-06-13
ES2624853T3 (es) 2017-07-17
EP2788359A1 (en) 2014-10-15
US20150057268A1 (en) 2015-02-26
EP2788359B1 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
US7935721B2 (en) Spiro-oxindole compounds and their uses as therapeutic agents
US9974777B2 (en) Tetrahydrocarboline derivative
KR20140129065A (ko) 축합 피롤디카복사미드 및 약제로서의 그의 용도
US20250250249A1 (en) Novel substituted benzimidazole derivatives as d-amino acid oxidase (daao) inhibitors
US9150582B2 (en) Composition and method for neuropeptide S receptor (NPSR) antagonists
HK1168104B (en) Spiro-oxindole compounds and their uses as therapeutic agents
HK1161873B (en) Spiro-oxindole compounds and their uses as therapeutic agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180706

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180710

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180718

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180731

R150 Certificate of patent or registration of utility model

Ref document number: 6381445

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250